Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Eledon Pharmaceuticals, Inc. (ELDN) had Return on Tangible Equity of -19.17% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-17.46M |
|
-- |
|
-- |
|
$19.07M |
|
$-19.07M |
|
$1.61M |
|
$-17.46M |
|
$-17.46M |
|
$-17.46M |
|
$-17.46M |
|
$-17.46M |
|
$-17.46M |
|
$-19.07M |
|
$-19.07M |
|
77.16M |
|
77.16M |
|
$-0.21 |
|
$-0.21 |
|
| Balance Sheet Financials | |
$96.30M |
|
-- |
|
$33.56M |
|
$129.86M |
|
$14.30M |
|
-- |
|
$24.51M |
|
$38.80M |
|
$35.36M |
|
$91.05M |
|
$91.05M |
|
59.88M |
|
| Cash Flow Statement Financials | |
$-48.25M |
|
$31.25M |
|
$0.12M |
|
$20.55M |
|
$3.67M |
|
$-16.88M |
|
$7.99M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.74 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-48.25M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-49.38% |
|
|
Return on Tangible Equity |
-19.17% |
-13.44% |
|
-19.17% |
|
$1.52 |
|
$-0.63 |
|
$-0.63 |
|